Tag: Colorectal

Stock

Pfizer’s BRAFTOVI ® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

25/01/2025
admin

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate…